Next 10 |
home / stock / ipsey / ipsey articles
Ipsen SA (OTC:IPSEF) (OTC:IPSEY) announced Monday that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Iqirvo (ela...
Ipsen's Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Ch...
PARIS, FRANCE, 2 May 2024 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointmen...
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages ...
PARIS, FRANCE, 7 December 2023 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital M...
ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR ?,? agonist for patients...
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("d...
PARIS, FRANCE, 4 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY) announced today the co-optation of Pascal Touchon to its Board as an indepen...
PARIS, FRANCE, 1 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen SA (OTC:IPSEF) (OTC:IPSEY) announced Monday that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Iqirvo (ela...
Ipsen's Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Ch...
PARIS, FRANCE, 2 May 2024 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointmen...